This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
In the present study, 113 patients were classified into four groups according to their cervical cytology, HPV infection and
follow up. Cytology samples were examined for aberrant DNA methylation (abMet) of DLX4 and SIM1 genes and their
protein expressions. CaSki cells were treated with 5-Aza-2´-deoxycytidine (5-aza-dC). Of 113 samples, 40 in Group-1 were
negative for intraepithelial lesion or malignancy. 21 low-grade squamous intraepithelial lesions (LSILs) in Group-2 showed a
continuance of LSIL for longer than 365 days and 12 LSILs in Group-3 showed an up-grading to high-grade (H) SIL+ within
365 days after the diagnosis of LSIL. 40 in Group-4 were squamous cell carcinoma. All but Group-1 was infected with highrisk
HPV. Significant difference existed in frequency of abMet between groups 2 and 3 (p=0.044), between groups-3 and 4
(p=0.020) for DLX4 and between Groups-1 and 3 (p=0.0003), as well as between Groups-2 and 3 (p=0.005) for SIM1 gene.
DLX4 protein expression was significantly reduced in the DLX4 abMet positive tissues as compared to the negative tissues
(p=0.008) and 5-aza-dC treatment extracted DLX4 protein expression of CaSki cells in a dose-dependent manner (p<0.005).
The LSIL cases with abMet of SIM1 gene or both genes progressed faster to HSIL+ than others (p=0.033 or p=0.048). Therefore,
AbMet of DLX4 and SIM1 genes should be a useful and novel progression marker of uterine cervical LSIL with HPV infection.
Kiyomi Taniyama has completed his PhD in Pathology at the Hiroshima University School of Medicine in Japan in 1985 and he learnt molecular techniques and laser capture microdissection at the University of California, San Diego Cancer Center. He has joined the National Hospital Organization (NHO), Kure Medical Center and Chugoku Cancer Center in 2002 and became the President in July 2014.